For pembrolizumab as second-line treatment for cervical cancer, the NCCN guidelines [33] recommend it for patients with a PD-L1 CPS > 1 and DNA mismatch-repair deficient (dMMR) or microsatellite instability-high (MSI-H) cases, but for all other patient subpopulations, recommendations for this drug by the guidelines are rated as category 2B. Here, CD274 is linked to cervical carcinoma.